Apexigen and Yale Cancer Center Collaborate to Evaluate APX005M, Cabiralizumab, and Opdivo in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

San Carlos, CA, and New Haven, CT – June 14, 2018 – Apexigen, Inc., and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen’s APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors. The Phase 1/2 clinical trial will evaluate the safety, tolerability, and preliminary activity of APX005M in combination with cabiralizumab …

More From BioPortfolio on "Apexigen and Yale Cancer Center Collaborate to Evaluate APX005M, Cabiralizumab, and Opdivo in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy"